시장보고서

상품코드

1722832

세계의 단백질 공학 시장 규모, 점유율, 동향, 예측 : 제품 및 서비스, 단백질 유형, 기술, 최종사용자, 지역별(2025-2033년)

Protein Engineering Market Size, Share, Trends and Forecast by Product & Services, Protein Type, Technology, End User and Region, 2025-2033

발행일: 2025년 05월 | 리서치사:

IMARC | 페이지 정보: 영문 134 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

단백질 공학 세계 시장 규모는 2024년 36억 달러에 달했습니다. 향후 IMARC Group은 이 시장이 2033년까지 82억 달러에 달하고, 2025-2033년 9.5%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측했습니다. 현재 북미가 시장을 독점하고 있으며, 2024년에는 40.6%라는 큰 시장 점유율을 차지했습니다. 인공지능(AI)을 통한 자동화는 단백질 모델링, 신약 개발, 산업용 효소 최적화를 강화하여 단백질 공학 시장 점유율을 확대하는 주요 요인으로 작용하고 있습니다. 정부의 재정 지원은 학술 연구를 지원하고 단백질 치료제 및 합성 생물학의 혁신을 가속화하고 있습니다.

단백질 공학은 원하는 결과를 얻기 위해 단백질 서열을 개발하거나 변경하는 과정을 말합니다. 새로운 단백질의 합성이나 기존 구조나 서열의 변경을 포함하며, 새로운 기능 강화를 위해 아미노산 서열을 변경하는 재조합 데옥시리보핵산(DNA) 기술을 이용합니다. 이 기술은 산업적으로 사용되는 효소 및 단백질의 대량 생산에 널리 이용되고 있습니다. 최근 연구자들은 의료, 연구, 산업, 건강, 생명공학 응용 분야에 적합한 다양한 단백질을 설계하는 데 성공하여 전 세계적으로 수요가 증가하고 있습니다.

단백질 공학 시장 동향 :

합성 생물학에 대한 투자 증가와 단백질 기반 의약품 개발에 대한 관심 증가가 시장 개척을 촉진하는 주요 요인으로 작용하고 있습니다. 또한, 단백질 의약품의 임상 결과가 양호하여 비단백질 의약품에서 단백질 치료제로의 전환이 두드러지게 나타나고 있습니다. 이는 단백질 결핍 질환의 확산과 함께 단백질 공학에 대한 수요를 증가시키고 있습니다. 또한, 단백질 공학 분야의 연구 및 개발(R&D) 활동에 대한 자금 지원 증가와 같은 여러 정부의 유리한 이니셔티브가 시장 성장을 가속하고 있습니다. 또한, 재조합 단일클론항체(mAbs)의 출현과 암 및 자가면역질환과 같은 다양한 질환의 치료에서 단일클론항체 사용량이 증가함에 따라 제품 채택률이 가속화되고 있습니다. 또한, 농약 업계에서는 작물 수확량을 늘리거나 바이오연료 생산을 촉진하기 위해 기능을 강화한 효소를 생산하기 위한 응용 연구가 진행되어 시장 성장의 촉매제가 되고 있습니다. 맞춤형 의약품에 대한 수요 증가, 바이오시밀러 및 생물학적 제제에 대한 수요 증가, 의료 인프라 개선, 기술 발전, 제품 혁신 등 다른 요인들도 시장 전망을 밝게 하고 있습니다.

본 보고서에서 다룬 주요 질문

단백질 공학 시장 규모는?
단백질 공학 시장 전망은?
단백질 공학 시장을 이끄는 주요 요인은?
단백질 공학 시장에서 가장 큰 점유율을 차지하는 지역은?
세계 단백질 공학 시장의 주요 기업은?

북미
- 미국
- 캐나다
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 인도네시아
- 기타
유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
라틴아메리카
- 브라질
- 멕시코
- 기타
중동 및 아프리카
- 시장 내역 : 국가별

제11장 SWOT 분석

개요
강점
약점
기회
위협

제12장 밸류체인 분석

제13장 Porter의 Five Forces 분석

개요
바이어의 교섭력
공급 기업의 교섭력
경쟁 정도
신규 진출업체의 위협
대체품의 위협

제14장 가격 분석

제15장 경쟁 구도

시장 구조
주요 기업
주요 기업 개요
- Abzena Ltd.
- Agilent Technologies Inc.
- Amgen Inc.
- Bio-Rad Laboratories Inc.
- Bruker Corporation
- Codexis Inc.
- Danaher Corporation
- Eli Lilly and Company
- General Electric Company
- Merck KGaA
- Novo Nordisk A/S
- PerkinElmer Inc.
- Thermo Fisher Scientific Inc.
- Waters Corporation

LSH 25.06.04

The global protein engineering market size was valued at USD 3.6 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 8.2 Billion by 2033, exhibiting a CAGR of 9.5% during 2025-2033. North America currently dominates the market, holding a significant market share of 40.6% in 2024. Artificial intelligence (AI-driven) automation enhances protein modeling, drug discovery, and industrial enzyme optimization, which is a key factor expanding the protein engineering market share. Government funding supports academic research, accelerating innovations in protein therapeutics and synthetic biology.

Protein engineering refers to the process of developing or changing a protein sequence to achieve the desired result. It involves the synthesis of new proteins or amendments in the existing structure or sequence and employs recombinant deoxyribonucleic acid (DNA) technology to alter amino acid sequences for novel and enhanced functions. It is widely utilized for the production of enzymes or proteins in large quantities for use in industrial settings. In recent years, researchers have successfully engineered a wide range of proteins tailored to medicine, research, industry, health, and biotechnology applications, which is escalating their demand across the globe.

Protein Engineering Market Trends:

The rising investments in synthetic biology and the improving focus toward protein-based drug development represent the primary factors driving the market growth. Additionally, there has been a significant shift toward protein therapeutics from non-protein drugs due to their associated positive clinical outcomes. This, in confluence with the widespread prevalence of protein-deficient diseases, is increasing the demand for protein engineering. Furthermore, several favorable initiatives undertaken by the government of various countries, such as increased funding for research and development (R&D) activities in the field of protein engineering, are propelling the market growth. Besides this, the advent of recombinant monoclonal antibodies (mAbs) and the increasing usage of monoclonal antibodies to treat various diseases, such as cancer and autoimmune diseases, are accelerating product adoption rates. Moreover, the ongoing research for applications of protein engineering in the agrochemical industry to generate enzymes with enhanced function to increase the crop yield or facilitate biofuel production is catalyzing the market growth. Other factors, including the escalating demand for personalized medicines, growing need for biosimilars and biologics, improving healthcare infrastructure, technological advancements, and product innovations, are also creating a positive outlook for the market.

Key Market Segmentation:

Breakup by Product & Services:

Instruments
Reagents
Services and Software

Breakup by Protein Type:

Insulin
Monoclonal Antibodies
Coagulation Factors
Vaccines
Growth Factors
Others

Breakup by Technology:

Irrational Protein Design
Rational Protein Design

Breakup by End User:

Pharmaceutical and Biotechnology Companies
Academic Research Institutes
Contract Research Organizations

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abzena Ltd., Agilent Technologies Inc., Amgen Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Codexis Inc., Danaher Corporation, Eli Lilly and Company, General Electric Company, Merck KGaA, Novo Nordisk A/S, PerkinElmer Inc., Thermo Fisher Scientific Inc. and Waters Corporation.

Key Questions Answered in This Report

1.How big is the protein engineering market?
2.What is the future outlook of protein engineering market?
3.What are the key factors driving the protein engineering market?
4.Which region accounts for the largest protein engineering market share?
5.Which are the leading companies in the global protein engineering market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Protein Engineering Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product & Services

6.1 Instruments
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Reagents
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Services and Software
- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 Market Breakup by Protein Type

7.1 Insulin
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Monoclonal Antibodies
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Coagulation Factors
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Vaccines
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Growth Factors
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast

8 Market Breakup by Technology

8.1 Irrational Protein Design
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Rational Protein Design
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by End User

9.1 Pharmaceutical and Biotechnology Companies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Academic Research Institutes
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Contract Research Organizations
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Abzena Ltd.
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
- 15.3.2 Agilent Technologies Inc.
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 Amgen Inc.
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 Bio-Rad Laboratories Inc.
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 Bruker Corporation
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
  - 15.3.5.4 SWOT Analysis
- 15.3.6 Codexis Inc.
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 Danaher Corporation
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 Eli Lilly and Company
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 General Electric Company
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Merck KGaA
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis
- 15.3.11 Novo Nordisk A/S
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
  - 15.3.11.4 SWOT Analysis
- 15.3.12 PerkinElmer Inc.
  - 15.3.12.1 Company Overview
  - 15.3.12.2 Product Portfolio
  - 15.3.12.3 Financials
  - 15.3.12.4 SWOT Analysis
- 15.3.13 Thermo Fisher Scientific Inc.
  - 15.3.13.1 Company Overview
  - 15.3.13.2 Product Portfolio
  - 15.3.13.3 Financials
  - 15.3.13.4 SWOT Analysis
- 15.3.14 Waters Corporation
  - 15.3.14.1 Company Overview
  - 15.3.14.2 Product Portfolio
  - 15.3.14.3 Financials
  - 15.3.14.4 SWOT Analysis